IBDEI2AJ ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,38859,1,3,0)
 ;;=3^Merkle Cell CA,Overlapping Sites
 ;;^UTILITY(U,$J,358.3,38859,1,4,0)
 ;;=4^C4A.8
 ;;^UTILITY(U,$J,358.3,38859,2)
 ;;=^5001157
 ;;^UTILITY(U,$J,358.3,38860,0)
 ;;=C4A.9^^151^1902^78
 ;;^UTILITY(U,$J,358.3,38860,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38860,1,3,0)
 ;;=3^Merkle Cell CA,Unspec
 ;;^UTILITY(U,$J,358.3,38860,1,4,0)
 ;;=4^C4A.9
 ;;^UTILITY(U,$J,358.3,38860,2)
 ;;=^5001158
 ;;^UTILITY(U,$J,358.3,38861,0)
 ;;=I78.1^^151^1903^8
 ;;^UTILITY(U,$J,358.3,38861,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38861,1,3,0)
 ;;=3^Nevus,Non-Neoplastic
 ;;^UTILITY(U,$J,358.3,38861,1,4,0)
 ;;=4^I78.1
 ;;^UTILITY(U,$J,358.3,38861,2)
 ;;=^269807
 ;;^UTILITY(U,$J,358.3,38862,0)
 ;;=L60.3^^151^1903^2
 ;;^UTILITY(U,$J,358.3,38862,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38862,1,3,0)
 ;;=3^Nail Dystrophy
 ;;^UTILITY(U,$J,358.3,38862,1,4,0)
 ;;=4^L60.3
 ;;^UTILITY(U,$J,358.3,38862,2)
 ;;=^5009236
 ;;^UTILITY(U,$J,358.3,38863,0)
 ;;=L92.1^^151^1903^4
 ;;^UTILITY(U,$J,358.3,38863,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38863,1,3,0)
 ;;=3^Necrobiosis Lipoidica NEC
 ;;^UTILITY(U,$J,358.3,38863,1,4,0)
 ;;=4^L92.1
 ;;^UTILITY(U,$J,358.3,38863,2)
 ;;=^5009462
 ;;^UTILITY(U,$J,358.3,38864,0)
 ;;=L20.81^^151^1903^7
 ;;^UTILITY(U,$J,358.3,38864,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38864,1,3,0)
 ;;=3^Neurodermatitis,Atopic
 ;;^UTILITY(U,$J,358.3,38864,1,4,0)
 ;;=4^L20.81
 ;;^UTILITY(U,$J,358.3,38864,2)
 ;;=^5009108
 ;;^UTILITY(U,$J,358.3,38865,0)
 ;;=D48.5^^151^1903^6
 ;;^UTILITY(U,$J,358.3,38865,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38865,1,3,0)
 ;;=3^Neoplasm,Skin,Uncertain Behavior
 ;;^UTILITY(U,$J,358.3,38865,1,4,0)
 ;;=4^D48.5
 ;;^UTILITY(U,$J,358.3,38865,2)
 ;;=^267777
 ;;^UTILITY(U,$J,358.3,38866,0)
 ;;=D49.2^^151^1903^5
 ;;^UTILITY(U,$J,358.3,38866,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38866,1,3,0)
 ;;=3^Neoplasm,Bone/Soft Tissue/Skin,Unspec Behavior
 ;;^UTILITY(U,$J,358.3,38866,1,4,0)
 ;;=4^D49.2
 ;;^UTILITY(U,$J,358.3,38866,2)
 ;;=^5002272
 ;;^UTILITY(U,$J,358.3,38867,0)
 ;;=L60.0^^151^1903^3
 ;;^UTILITY(U,$J,358.3,38867,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38867,1,3,0)
 ;;=3^Nail,Ingrowing
 ;;^UTILITY(U,$J,358.3,38867,1,4,0)
 ;;=4^L60.0
 ;;^UTILITY(U,$J,358.3,38867,2)
 ;;=^5009234
 ;;^UTILITY(U,$J,358.3,38868,0)
 ;;=L60.9^^151^1903^1
 ;;^UTILITY(U,$J,358.3,38868,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38868,1,3,0)
 ;;=3^Nail Disorder,Unspec
 ;;^UTILITY(U,$J,358.3,38868,1,4,0)
 ;;=4^L60.9
 ;;^UTILITY(U,$J,358.3,38868,2)
 ;;=^5009240
 ;;^UTILITY(U,$J,358.3,38869,0)
 ;;=Z91.19^^151^1903^9
 ;;^UTILITY(U,$J,358.3,38869,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38869,1,3,0)
 ;;=3^Noncompliance w/ Medical Treatment/Regimen
 ;;^UTILITY(U,$J,358.3,38869,1,4,0)
 ;;=4^Z91.19
 ;;^UTILITY(U,$J,358.3,38869,2)
 ;;=^5063618
 ;;^UTILITY(U,$J,358.3,38870,0)
 ;;=E80.1^^151^1904^20
 ;;^UTILITY(U,$J,358.3,38870,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38870,1,3,0)
 ;;=3^Porphyria Cutanea Tarda
 ;;^UTILITY(U,$J,358.3,38870,1,4,0)
 ;;=4^E80.1
 ;;^UTILITY(U,$J,358.3,38870,2)
 ;;=^5002982
 ;;^UTILITY(U,$J,358.3,38871,0)
 ;;=L56.4^^151^1904^19
 ;;^UTILITY(U,$J,358.3,38871,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38871,1,3,0)
 ;;=3^Polymorphous Light Eruption
 ;;^UTILITY(U,$J,358.3,38871,1,4,0)
 ;;=4^L56.4
 ;;^UTILITY(U,$J,358.3,38871,2)
 ;;=^5009218
 ;;^UTILITY(U,$J,358.3,38872,0)
 ;;=L10.0^^151^1904^4
 ;;^UTILITY(U,$J,358.3,38872,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38872,1,3,0)
 ;;=3^Pemphigus Vulgaris
 ;;^UTILITY(U,$J,358.3,38872,1,4,0)
 ;;=4^L10.0
